SAB Welcomes Five New Members 

The Lymphoma Research Foundation's (LRF) Scientific Advisory Board (SAB) recently held elections for new board members. Five well-esteemed lymphoma researchers from across the country were selected to serve five-year terms. LRF is proud to welcome Ranjana Advani, MD, Stephen Ansell, MD, PhD, Nancy Bartlett, MD, Myron Czuczman, MD and Craig Moskowitz, MD to the SAB.

Ranjana Advani, MD (Stanford University School of Medicine)
Ranjana Advani, MD is an Associate Professor of Medicine/Oncology at the Stanford University School of Medicine. She received her medical degree from Bombay University, completed her internship at Santa Clara Valley Medical Center and her residency and fellowship at Stanford University Medical Center. Currently, Dr. Advani's research interests are in Hodgkin lymphomas, non-Hodgkin lymphomas and cutaneous lymphomas. Her research program is highly collaborative with radiation oncology, industry, pathology and dermatology.

Stephen Ansell, MD, PhD (Mayo Medical School)
Stephen Ansell, MD, PhD is a professor of Medicine at Mayo Medical School. He received his medical degree and doctorate of philosophy from, as well as completed his fellowship and residency, at the University of Pretoria in South Africa. He then completed the rest of his medical education at Mayo Medical School. His lab is currently investigating the phenotype and activity of intratumoral T-cells and developing strategies to modulate the T-cell infiltration in areas of B-cell lymphoma. These studies are being conducted within the Division of Hematology at the Mayo Clinic, the Mayo Clinic Cancer Center and the North Central Cancer Treatment Group.

Nancy Bartlett, MD (Washington University Siteman Cancer Center in St. Louis)
Nancy Bartlett is a Professor of Medicine and the Koman Chair in Medical Oncology at Washington University and the Siteman Cancer Center in St. Louis. She received her medical degree from Washington University and completed her internal medicine residency and chief residency at the University of California, San Francisco and a postdoctoral fellowship in medical oncology at Stanford University. Her primary research interest is in developing and conducting clinical trials for patients with newly diagnosed or relapsed Hodgkin lymphoma.

Myron Czuczman, MD (Roswell Park Cancer Institute)
Myron Czuczman, MD is the Chief of the Lymphoma/Myeloma Services and Professor of Oncology in the Department of Medicine and the Head of the Lymphoma Translational Research Laboratory at Roswell Park Cancer Institute. Dr. Czuczman is also a Professor of Medicine at the School of Medicine and Biomedical Sciences, State University of New York at Buffalo. He received his medical degree from the Pennsylvania State University College of Medicine, completed his residency at North Shore University Hospital and fellowship at the Memorial Sloan-Kettering Cancer Center. His research focus is on monoclonal antibodies and cutting-edge novel targeted therapies either alone or in combination with other agents in the treatment of lymphoid neoplasms and evaluating the significance of minimal residual disease in lymphoid malignancies.

Craig Moskowitz, MD (Memorial Sloan-Kettering Cancer Center)
Craig Moskowitz, MD is the Clinical Director of the Division of Hematologic Oncology at the Memorial Sloan-Kettering Cancer Center. Dr. Moskowitz is the Principal Investigator for a number of clinical trials aimed at improving the care of patients with lymphoma. Dr. Moskowitz received his medical degree from Wayne State University School of Medicine, completed his residency at the Bronx Municipal Hospital Center and Albert Einstein College of Medicine. He completed his fellowship at Memorial Sloan-Kettering Cancer Center. His research has focused on improving the outcome of patients with poor-risk diffuse large B-cell lymphoma and Hodgkin lymphoma.